FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366292021> ?p ?o ?g. }

• W4366292021 abstract "Background: Colorectal cancer (CRC) ranks third globally. There are many adverse reactions to treatments such as surgeries and post-surgical chemotherapy, which affect patients' prognosis and reduce their life quality. Omega-3 polyunsaturated fatty acids (O3FAs) have become an essential part of immune nutrition due to their anti-inflammatory properties, which improve body immunity and have attracted widespread attention. A systematic review focused on the efficacy and safety of O3FAs for patients undergoing surgeries in combination with chemotherapy or a surgery alone is lacking. Objectives: To evaluate the efficacy of O3FAs in the adjuvant treatment of CRC, a meta-analysis was conducted on patients with CRC who underwent surgeries in combination with chemotherapy or a surgery alone. Methods: As of March 2023, publications have been obtained using search terms from digital databases such as PubMed, Web of Science, Embase and Cochrane Library. Only randomized clinical trials (RCTs) evaluating the efficacy and safety of O3FAs following adjuvant treatments for CRC were included in the meta-analysis. Key outcomes were tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-1beta (IL-1β), albumin, body mass index (BMI), weight, the rate of infectious and non-infectious complications, the length of hospital stay (LOS), CRC mortality and life quality. Results: After screening 1,080 studies, 19 RCTs (n = 1,556) with O3FAs in CRC were included, in all of which at least one efficacy or safety outcome was examined. Compared to the control group, the level of TNF-α (MD = -0.79, 95% CI: 1.51 to -0.07, p = 0.03) and IL-6 was reduced due to O3FA-enriched nutrition during the perioperative period (MD = -4.70, 95% CI: 6.59 to -2.80, p < 0.00001). It also reduces LOS (MD = 9.36, 95% CI: 2.16 to 16.57, p = 0.01). No significant differences were found in CRP, IL-1β, albumin, BMI, weight, the rate of infectious and non-infectious complications, CRC mortality or life quality. The inflammatory status of patients with CRC undergoing adjuvant therapies decreased after a total parenteral nutrition (TPN) O3FA supplementation (TNF-α, MD = -1.26, 95% CI: 2.25 to -0.27, p = 0.01, I2 = 4%, n = 183 participants). The rate of infectious and non-infectious complications was reduced among patients with CRC undergoing adjuvant therapies after a parenteral nutrition (PN) O3FA supplementation (RR = 3.73, 95% CI: 1.52 to 9.17, p = 0.004, I2 = 0%, n = 76 participants). Conclusion: Our observations suggest that supplementation with O3FAs has little or no effect on patients with CRC undergoing adjuvant therapies and that a prolonged inflammatory state may be modified. To validate these findings, well-designed, large-scale, randomized and controlled studies on homogeneous patient populations are expected." @default.
• W4366292021 created "2023-04-20" @default.
• W4366292021 creator A5023253950 @default.
• W4366292021 creator A5025211600 @default.
• W4366292021 creator A5027900982 @default.
• W4366292021 creator A5065701868 @default.
• W4366292021 creator A5084302554 @default.
• W4366292021 date "2023-04-18" @default.
• W4366292021 modified "2023-10-13" @default.
• W4366292021 title "Efficacy and safety of Omega-3 polyunsaturated fatty acids in adjuvant treatments for colorectal cancer: A meta-analysis of randomized controlled trials" @default.
• W4366292021 cites W1978447671 @default.
• W4366292021 cites W1980276814 @default.
• W4366292021 cites W1987341221 @default.
• W4366292021 cites W2000537420 @default.
• W4366292021 cites W2025651303 @default.
• W4366292021 cites W2036468160 @default.
• W4366292021 cites W2052088613 @default.
• W4366292021 cites W2062470198 @default.
• W4366292021 cites W2068488099 @default.
• W4366292021 cites W2090807187 @default.
• W4366292021 cites W2095762159 @default.
• W4366292021 cites W2097506360 @default.
• W4366292021 cites W2111067528 @default.
• W4366292021 cites W2117214964 @default.
• W4366292021 cites W2118704546 @default.
• W4366292021 cites W2127188645 @default.
• W4366292021 cites W2132288432 @default.
• W4366292021 cites W2142175984 @default.
• W4366292021 cites W2144929457 @default.
• W4366292021 cites W2151172513 @default.
• W4366292021 cites W2156826845 @default.
• W4366292021 cites W2157823046 @default.
• W4366292021 cites W2163503224 @default.
• W4366292021 cites W2169239408 @default.
• W4366292021 cites W2170892587 @default.
• W4366292021 cites W2342895502 @default.
• W4366292021 cites W2468591787 @default.
• W4366292021 cites W2560013764 @default.
• W4366292021 cites W2612213392 @default.
• W4366292021 cites W2751718745 @default.
• W4366292021 cites W2754394790 @default.
• W4366292021 cites W2797024694 @default.
• W4366292021 cites W2799676937 @default.
• W4366292021 cites W2802374582 @default.
• W4366292021 cites W2811217156 @default.
• W4366292021 cites W2900583498 @default.
• W4366292021 cites W2902161659 @default.
• W4366292021 cites W2946325966 @default.
• W4366292021 cites W2972126945 @default.
• W4366292021 cites W2979806443 @default.
• W4366292021 cites W2981370247 @default.
• W4366292021 cites W2996122639 @default.
• W4366292021 cites W3001233619 @default.
• W4366292021 cites W3003180891 @default.
• W4366292021 cites W3021076331 @default.
• W4366292021 cites W3083934892 @default.
• W4366292021 cites W3099091911 @default.
• W4366292021 cites W3103104242 @default.
• W4366292021 cites W3111048029 @default.
• W4366292021 cites W3112147815 @default.
• W4366292021 cites W3118615836 @default.
• W4366292021 cites W3119738945 @default.
• W4366292021 cites W3128646645 @default.
• W4366292021 cites W3136000048 @default.
• W4366292021 cites W3184775172 @default.
• W4366292021 cites W3188383170 @default.
• W4366292021 cites W3203341316 @default.
• W4366292021 cites W4200610833 @default.
• W4366292021 cites W4213435918 @default.
• W4366292021 cites W4220686216 @default.
• W4366292021 cites W4220876580 @default.
• W4366292021 cites W4288060571 @default.
• W4366292021 cites W4288747220 @default.
• W4366292021 cites W4321332154 @default.
• W4366292021 cites W94786304 @default.
• W4366292021 doi "https://doi.org/10.3389/fphar.2023.1004465" @default.
• W4366292021 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37144220" @default.
• W4366292021 hasPublicationYear "2023" @default.
• W4366292021 type Work @default.
• W4366292021 citedByCount "2" @default.
• W4366292021 countsByYear W43662920212023 @default.
• W4366292021 crossrefType "journal-article" @default.
• W4366292021 hasAuthorship W4366292021A5023253950 @default.
• W4366292021 hasAuthorship W4366292021A5025211600 @default.
• W4366292021 hasAuthorship W4366292021A5027900982 @default.
• W4366292021 hasAuthorship W4366292021A5065701868 @default.
• W4366292021 hasAuthorship W4366292021A5084302554 @default.
• W4366292021 hasBestOaLocation W43662920211 @default.
• W4366292021 hasConcept C121608353 @default.
• W4366292021 hasConcept C126322002 @default.
• W4366292021 hasConcept C141071460 @default.
• W4366292021 hasConcept C143998085 @default.
• W4366292021 hasConcept C168563851 @default.
• W4366292021 hasConcept C197934379 @default.
• W4366292021 hasConcept C2776478404 @default.
• W4366292021 hasConcept C2777863537 @default.
• W4366292021 hasConcept C526805850 @default.
• W4366292021 hasConcept C71924100 @default.
• W4366292021 hasConcept C90924648 @default.
• W4366292021 hasConcept C95190672 @default.

• next